Last updated on May 9, 2024.
See also: Generic Adderall XR
See Also
St. Antonius Apotheek | St. Antonius Ziekenhuis‘I’m fed up’: Frustrations grow as ADHD drug shortage continuesAdderall is a brand name of amphetamine/dextroamphetamine, approved by the FDA in the following formulation(s):
ADDERALL 10 (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate - tablet;oral)
- Manufacturer: TEVA WOMENS
Approval date: February 13, 1996
Strength(s): 2.5MG;2.5MG;2.5MG;2.5MG (discontinued) [RLD] [AB] - Manufacturer: TEVA WOMENS
Approval date: August 31, 2000
Strength(s): 3.125MG;3.125MG;3.125MG;3.125MG (discontinued) [RLD] [AB] - Manufacturer: TEVA WOMENS
Approval date: August 31, 2000
Strength(s): 3.75MG;3.75MG;3.75MG;3.75MG (discontinued) [RLD] [AB] - Manufacturer: TEVA WOMENS
Approval date: February 13, 1996
Strength(s): 5MG;5MG;5MG;5MG (discontinued) [RLD] [AB] - Manufacturer: TEVA WOMENS
Approval date: May 12, 1997
Strength(s): 7.5MG;7.5MG;7.5MG;7.5MG (discontinued) [RLD] [AB] - Manufacturer: TEVA WOMENS
Approval date: May 12, 1997
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG (discontinued) [RLD] [AB] - Manufacturer: TEVA WOMENS
Approval date: August 31, 2000
Strength(s): 1.875MG;1.875MG;1.875MG;1.875MG (discontinued) [RLD] [AB]
All of the above formulations have been discontinued.
Has a generic version of Adderall been approved?
Yes. The following products are equivalent to Adderall:
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate tablet;oral)
- Manufacturer: ACTAVIS ELIZABETH
Approval date: February 5, 2016
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: ALKEM LABS LTD
Approval date: October 6, 2023
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: ALVOGEN
Approval date: July 28, 2017
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: ASCENT PHARMS INC
Approval date: April 22, 2021
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: AUROLIFE PHARMA LLC
Approval date: November 27, 2013
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: BARR
Approval date: February 11, 2002
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: BARR
Approval date: March 19, 2003
Strength(s): 1.875MG;1.875MG;1.875MG;1.875MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB] - Manufacturer: ELITE LABS INC
Approval date: December 7, 2018
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: EPIC PHARMA LLC
Approval date: June 19, 2002
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: EPIC PHARMA LLC
Approval date: November 3, 2014
Strength(s): 1.875MG;1.875MG;1.875MG;1.875MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB] - Manufacturer: GRANULES
Approval date: December 28, 2021
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: LANNETT CO INC
Approval date: July 8, 2022
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: NUVO PHARM
Approval date: December 28, 2017
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: RHODES PHARMS
Approval date: January 13, 2021
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: SANDOZ
Approval date: June 14, 2002
Strength(s): 2.5MG;2.5MG;2.5MG;2.5MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: SANDOZ
Approval date: September 27, 2002
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB] - Manufacturer: SPECGX LLC
Approval date: October 7, 2003
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: SUN PHARM INDUSTRIES
Approval date: September 9, 2003
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: USPHARMA WINDLAS
Approval date: April 3, 2020
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB] - Manufacturer: ZYDUS PHARMS
Approval date: October 31, 2017
Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adderall. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Adderall (amphetamine / dextroamphetamine)
- Check interactions
- Compare alternatives
- Reviews (487)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: CNS stimulants
- En español
Patient resources
- Adderall drug information
Other brands
Mydayis
Professional resources
- Adderall prescribing information
- Amphetamine (AHFS Monograph)
Other brands
Mydayis
Other formulations
- Adderall XR
Related treatment guides
- ADHD
- Narcolepsy
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circ*mstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circ*mstances.
Medical Disclaimer
